Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2024. The report is available as an attached document and on the Company’s website, https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.
Latest press releases
Stayble provides update on partnership activities
Stayble Therapeutics AB (“Stayble” or “the Company”) today provides an update on the ongoing work to establish partnerships for the pain treatment STA363. The Company is encouraged by the strong interest shown by both mid-sized and large pharmaceutical companies. The Board and management assess that there are good opportunities to enter into a partnership agreement based on the available Phase 1b results.
(SV) – Stayble Therapeutics AB (publ) offentliggör utfallet av utnyttjande av teckningsoptioner av serie TO2
EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I STAYBLE THERAPEUTICS AB (PUBL). SE ÄVEN AVSNITTET ”VIKTIG INFORMATION” NEDAN.
Stayble Therapeutics AB (publ) (”Stayble” eller ”Bolaget”) offentliggör idag utfallet av utnyttjandet av teckningsoptioner av serie TO2 (”Teckningsoptionerna”) som emitterades i samband med Bolagets riktade emission av units som Bolagets styrelse beslutade om den 11 juni 2024. Totalt tecknades 8 000 000 aktier med stöd av Teckningsoptionerna, innebärande en nyttjandegrad om 100 procent. Stayble tillförs cirka 2 640 000 SEK före avdrag för transaktionskostnader.
Abstract on the effect of STA363 on disc volume from the phase 1b study has been accepted for oral presentation at a major international congress
Stayble Therapeutics AB (“Stayble” or “the Company”) announces that its scientific abstract on the effect of STA363 on disc volume reduction in patients with lumbar disc herniation has been accepted for an oral presentation at the Annual Meeting of the International Society for the Study of the Lumbar Spine (ISSLS) in Atlanta, USA, May 12–16, 2025.
Press photos
In need of press photos? Contact us for a curated collection of images and logotypes approved for use in editorial purposes.
Upcoming events
No events planned at the moment
Get all the latest news
Or connect with us on social media
LATEST ARTICLES AND COMPANY ANALYSIS
INVEST IN THE FUTURE TREATMENT OF CHRONIC BACK AND LEG PAIN
Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.
Investors